- Home
- /
- Blog
News
At Cell-Easy, we provide end-to-end GMP manufacturing services for advanced therapy medicinal products (ATMPs), with a strong focus on compliance, scalability, and reliability.
We help biotech and pharma companies bring innovative cell therapies from the lab to the clinic by combining high-quality starting material sourcing, robust process development, and clinical-grade GMP production that meets international standards (MHRA, ANSM, EMA, FDA readiness).
Whether you need early clinical batches or large-scale production, our tailored solutions optimize your process, minimize risks, and accelerate time-to-clinic.
Mastering Cell Bank Development and Manufacturing Services for US Pharma company
Learn more: Mastering Cell Bank Development and Manufacturing Services for US Pharma companyMastering Cell Bank Development and Manufacturing Services for US Pharma company Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services. Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell Bank…
Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy
Learn more: Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T TherapyCell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy This agreement with a pioneer European C&G company will soon enable the initiation of new clinical trials in South of France based on innovative CAR-T cell treatments The French Contract Development and Manufacturing Organization (CDMO) Cell-Easy stands out and…
Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse)
Learn more: Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse)Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) This agreement between the two…
IMPD Approval for FIH Trial in Systemic Sclerosis – Cell Easy
Learn more: IMPD Approval for FIH Trial in Systemic Sclerosis – Cell EasyIMPD Approval for FIH Trial in Systemic Sclerosis – Cell Easy EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they…
Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer
Learn more: Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific OfficerCell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer. Over the years, Cell-Easy has recognized the challenges faced by biotechs in bridging the…
IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy
Learn more: IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapyIUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy IUCT-Oncopole – Nouvelle fenêtre and Cell-Easy announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This partnership aims to drive innovation in public health and improve access to promising new cancer…